Abstract:
Oseltamivir (pronounced os-el-ta-mi-veer; Tamiflu--Roche), an oral anti-influenza drug that inhibits influenza virus neuraminidase, is now available in the UK. It has recently been licensed throughout the EU for use, when influenza is circulating in the community, in the treatment of patients with early influenza-like symptoms, and for prophylaxis in people who have had close contact with someone with influenza. Oseltamivir is the second neuraminidase inhibitor to be licensed in the UK, the other being zanamivir (Relenza--GlaxoSmithKline), which is taken by inhalation and licensed only for treatment. Previously, we concluded that there was insufficient evidence that treatment with zanamivir prevented serious complications in people most at risk from influenza to recommend its use. Here we review the efficacy and safety of oseltamivir and discuss its role in the management of influenza.
Insights
Oseltamivir (Tamiflu) is an oral antiviral for influenza treatment and prophylaxis. This review examines its efficacy and safety, discussing its role in managing influenza infections.
Area of Science:
- Virology
- Pharmacology
- Public Health
Background:
- Oseltamivir (Tamiflu) is a novel oral antiviral medication.
- It targets the neuraminidase enzyme of the influenza virus.
- Oseltamivir has received EU-wide licensing for influenza treatment and prophylaxis.
Purpose of the Study:
- To review the efficacy and safety of oseltamivir.
- To discuss the role of oseltamivir in influenza management.
- To compare oseltamivir with zanamivir, another neuraminidase inhibitor.
Main Methods:
- Literature review of clinical studies on oseltamivir.
- Analysis of efficacy data for treatment and prophylaxis.
- Assessment of safety profiles and adverse events.
Main Results:
- Oseltamivir is licensed for early treatment of influenza and post-exposure prophylaxis.
- It is the second neuraminidase inhibitor available in the UK, following zanamivir.
- Previous concerns regarding zanamivir's efficacy in preventing serious complications are noted.
Conclusions:
- Oseltamivir offers a new oral option for influenza management.
- Further discussion on its clinical utility and comparison with existing treatments is warranted.
- The review aims to inform healthcare professionals about oseltamivir's place in influenza control.
Related Concept Videos
Influenza
Inhibitors Of Virion Release
Respiratory Syncytial Virus Disease
Inhibitors of Viral Protein Synthesis
Leaky Scanning
Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:


